IsoPlexis (IsoPlexis) EPS (Basic) : $-2.70 (TTM As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is IsoPlexis EPS (Basic)?

IsoPlexis's basic earnings per share (Basic EPS) for the three months ended in Dec. 2022 was $-0.84. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2022 was $-2.70.

IsoPlexis's EPS (Diluted) for the three months ended in Dec. 2022 was $-0.84. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $-2.70.

IsoPlexis's EPS without NRI for the three months ended in Dec. 2022 was $-0.84. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2022 was -2.70.

During the past 3 years, the average EPS without NRI Growth Rate was -90.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, IsoPlexis's highest 3-Year average EPS without NRI Growth Rate was -90.80% per year. The lowest was -90.80% per year. And the median was -90.80% per year.

IsoPlexis EPS (Basic) Historical Data

The historical data trend for IsoPlexis's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IsoPlexis EPS (Basic) Chart

IsoPlexis Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

EPS (Basic)

-0.39

-13.71

-8.99

-2.70

IsoPlexis Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EPS (Basic)	Get a 7-Day Free Trial								-0.66	-0.74	-0.65	-0.47	-0.84

IsoPlexis EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

IsoPlexis's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-105.997	-	0)	/	39.318
	=	-2.70

IsoPlexis's Basic EPS for the quarter that ended in Dec. 2022 is calculated as

Basic EPS (Q: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-33.212	-	0)	/	39.590
	=	-0.84

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.70

IsoPlexis (NAS:ISO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

IsoPlexis EPS (Basic) Related Terms

Thank you for viewing the detailed overview of IsoPlexis's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

IsoPlexis (IsoPlexis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 North East Industrial Road, Branford, CT, USA, 06405

Website

https://www.isoplexis.com

IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines.

Executives

Nachum Shamir	director	12212 TECHNOLOGY BLVD, AUSTIN TX 78727
John Strahley	officer: Chief Financial Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Sean Mackay	director, officer: Chief Executive Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rew Richard W. Ii	officer: SVP, GC & Secretary	7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
James R Heath	director	C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405
Michael Egholm	director	1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110
Siddhartha Kadia	director	7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Jason W. Myers	director	C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301
John G. Conley	director	396 GREAT MEADOWS RD, CONCORD MA 01742-1803
Gregory P. Ho	director, 10 percent owner	C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Peter Siesel	officer: Chief Commercial Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Jing Zhou	officer: Chief Scientific Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rajesh T. Khakhar	officer: VP, Finance	35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405
Northpond Capital Gp, Llc	10 percent owner	4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003